Medium materiality6/10
UBS cuts Integra LifeSciences price target to $14 from $19
Why it may matterVerify against the original reporting
Bearish analyst revision, tempered by the new target remaining above the posted price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS reduced its IART target by about 26%, a substantial downward revision. The new target remains above the posted price of $11.94, so the update is negative but does not imply a below-market target.
- UBS cut its IART target 26% to $14; posted price was $11.94.
Key facts
- 01
Target: $14
- 02
Posted price: $11.94
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.